Abstract:Immunomagnetic capturing/detection of biomarkers, including immunoprecipitation‐mass‐spectrometry (IP‐MS) and single molecule array (Simoa®), is a key technology in biofluidic‐based in vitro diagnosis of Alzheimer’s disease (AD). However, proteins and other biomolecules in samples can non‐specifically absorb on the surface of biomarker‐targeting ligand functionalized capturing agents, such as commercial magnetic beads (Dynabeads®). Such “biofouling” effect leads to the formation of a “protein corona” that not only attenuates the detection specificity, sensitivity and reproducibility by blocking the binding of targeted biomarkers, but also creates strong “contaminating” background signals. This report introduces a polyethylene glycol‐block‐allyl glycidyl ether (PEG‐b‐AGE) polymer coated magnetic iron oxide nanoparticle (IONP) rendering anti‐biofouling capability to improve the sensitivity of blood‐sample‐based AD biomarker detection. Non‐specifically adsorbed proteins on Dynabeads® and anti‐biofouling IONP after incubating with human serum were quantified to evaluate biofouling effect. Dynabeads® and IONP were conjugated with antibodies, and compared for the detection of fluorescent dye FITC‐labeled AD biomarkers spiked in human serum (10 to 2000 pg/mL), including Aβ40, Aβ42, and phosphorylated tau (p‐tau181), which were quantified by fluorescence. To compare the detection in the settings of current platforms, spiked Aβ40 and Aβ42 in human serum were measured by IP‐MS using antibody‐conjugated Dynabeads® and IONP as the capturing agents. Antibodies in assay kits of Simoa® were used to conjugated with Dynabeads® and IONP to compare the detection of five AD biomarkers spiked in human serum in the Simoa® setting. Additionally, plasma samples from 21 AD patients were tested for Aβ40 and Aβ42 measurement using antibody‐conjugated IONP and Dynabeads® by IP‐MS. Anti‐biofouling IONP demonstrated a ∼20‐fold reduction in serum protein adsorption, comparing to Dynabeads®. Dynabeads® and IONP demonstrated comparable detection sensitivity (captured/spiked, %) when spiked AD biomarkers at the concentration of ∼200‐2000 pg/mL. However, in samples with spiked AD biomarkers at ∼10‐100 pg/mL, Dynabeads® showed a decreased sensitivity up to 29% comparing to IONP. When Aβ40 and Aβ42 in patient plasma samples were immunoprecipitated by IONP or Dynabeads and analyzed by mass‐spectrometry, IONP showed 1.8‐ to 23.5‐folds greater signal‐to‐noise ratio (peak intensity/baseline) than Dynabeads®. Anti‐biofouling IONP demonstrated improved sensitivity in blood‐based AD biomarker detections over Dynabeads®.

Enhancing Sensitivity of Immunomagnetic Detection of Alzheimer’s Disease Biomarkers with Magnetic Nanoparticles and Anti‐Biofouling Coating

Improving Sensitivity and Specificity of Amyloid-β Peptides and Tau Protein Detection with Antibiofouling Magnetic Nanoparticles for Liquid Biopsy of Alzheimer's Disease

Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay

In-situ nanozyme catalytic amplification coupled with a universal antibody orientation strategy based electrochemical immunosensor for AD-related biomarker

Multifunctional Superparamagnetic Iron Oxide Nanoparticles Conjugated with Aβ Oligomer-Specific scFv Antibody and Class A Scavenger Receptor Activator Show Early Diagnostic Potentials for Alzheimer's Disease

Highly Sensitive/selective 3D Nanostructured Immunoparticle-Based Interface on a Multichannel Sensor Array for Detecting Amyloid-Beta in Alzheimer's Disease

Preparation of Amyloid Immuno-Nanoparticles as Potential MRI Contrast Agents for Alzheimer's Disease Diagnosis.

Evaluation of Dimercaptosuccinic Acid-Coated Iron Nanoparticles Immunotargeted to Amyloid Beta as MRI Contrast Agents for the Diagnosis of Alzheimer's Disease

Sensitive detection of multiple blood biomarkers via immunomagnetic exosomal PCR for the diagnosis of Alzheimer's disease

PEG- b -AGE Polymer Coated Magnetic Nanoparticle Probes with Facile Functionalization and Anti-fouling Properties for Reducing Non-specific Uptake and Improving Biomarker Targeting.

Electrochemical Analysis of Amyloid Plaques and ApoE4 with Chitosan-Coated Gold Nanostars for Alzheimer's Detection

Regenerable and Simultaneous Surface Plasmon Resonance Detection of Aβ(1−40) and Aβ(1−42) Peptides in Cerebrospinal Fluids with Signal Amplification by Streptavidin Conjugated to an N-Terminus-Specific Antibody

Hybridization chain reaction triggered poly adenine to absorb silver nanoparticles for label-free electrochemical detection of Alzheimer's disease biomarkers amyloid β-peptide oligomers

Self-calibrating surface-enhanced Raman scattering-lateral flow immunoassay for determination of amyloid-β biomarker of Alzheimer's disease

Freestanding Nanofiber‐Assembled Aptasensor for Precisely and Ultrafast Electrochemical Detection of Alzheimer's Disease Biomarkers

Superparamagnetic iron oxide nanoparticles conjugated with Aβ oligomer-specific scFv antibody and class A scavenger receptor activator show therapeutic potentials for Alzheimer’s Disease

Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms - A critical review

Bioinspired Synthesis of ZnO@polydopamine/Au for Label-Free Photoelectrochemical Immunoassay of Amyloid-β Protein

Electrochemical Detection Of Beta-Amyloid Peptides On Electrode Covered With N-Terminus-Specific Antibody Based On Electrocatalytic O-2 Reduction By A Beta(1-16)-Heme-Modified Gold Nanoparticles

Aptamer-Functionalized Carbon Nanotube Field-Effect Transistor Biosensors for Alzheimer's Disease Serum Biomarker Detection.

Aptamer-Functionalized Carbon Nanotube Field-Effect Transistor Biosensors for Alzheimer’s Disease Serum Biomarker Detection